We developed a high throughput, efficient technology to screen new targets for cancer therapy. The technology based on the tissues and cell of cancer patients, gathering the new mouse antibody drug candidate. It can provide us not only the new target for cancer therapy but also the mouse antibody as the antibody drug candidate in large scale.
This technology is so mature that it had already provided us more than 6 potential new targets. And we have published paper on international leading journals on it, which showed the effectiveness and commonality of it. So it will provide our company the new candidate for the pipeline in the future, and help us win in the global competition.